within Pharmacolibrary.Drugs.ATC.N;

model N06AA06
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.41,
    Cl             = 9.166666666666666e-06,
    adminDuration  = 600,
    adminMass      = 75 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0197,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.002,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.0127,
    k12             = 0.38,
    k21             = 0.38
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N06AA06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Trimipramine is a tricyclic antidepressant (TCA) used primarily in the treatment of depressive disorders and sometimes insomnia. It is an approved drug in some countries, though its use has declined due to the advent of selective serotonin reuptake inhibitors (SSRIs) and other newer antidepressants.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters observed in healthy adult volunteers after single oral dose administration.</p><h4>References</h4><ol><li><p>Kirchheiner, J, Sasse, J, Meineke, I, Roots, I, &amp; Brockmöller, J (2003). Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity. <i>Pharmacogenetics</i> 13(12) 721–728. DOI:<a href=\"https://doi.org/10.1097/00008571-200312000-00003\">10.1097/00008571-200312000-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14646691/\">https://pubmed.ncbi.nlm.nih.gov/14646691</a></p></li><li><p>Fernandez, C, Martin, C, Gimenez, F, &amp; Farinotti, R (1995). Clinical pharmacokinetics of zopiclone. <i>Clinical pharmacokinetics</i> 29(6) 431–441. DOI:<a href=\"https://doi.org/10.2165/00003088-199529060-00004\">10.2165/00003088-199529060-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8787948/\">https://pubmed.ncbi.nlm.nih.gov/8787948</a></p></li><li><p>Eap, CB, Laurian, S, Souche, A, Koeb, L, Reymond, P, Buclin, T, &amp; Baumann, P (1992). Influence of quinidine on the pharmacokinetics of trimipramine and on its effect on the waking EEG of healthy volunteers. A pilot study on two subjects. <i>Neuropsychobiology</i> 25(4) 214–220. DOI:<a href=\"https://doi.org/10.1159/000118840\">10.1159/000118840</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1454163/\">https://pubmed.ncbi.nlm.nih.gov/1454163</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N06AA06;
